Mr. Hugh Rogers reports

BIONXT SOLUTIONS PREPARES FOR HUMAN BIOEQUIVALENCE STUDY FOR MS

Bionxt Solutions Inc. has advanced preparation for its human bioequivalence study for its lead multiple sclerosis (MS) treatment.

Bionxt's lead product, BNT23001, is a proprietary sublingual thin-film formulation of cladribine for the treatment of MS. Preclinical studies, as reported in internal research data and third party evaluations, have demonstrated high absorption rates and bioequivalence compared with existing oral tablet therapies. The company has purchased cladribine active pharmaceutical ingredient, which is necessary to complete the technology transfer process with Gen-Plus, its European contract research and development organization (CRDO), in Munich, Germany. Once commenced, the bioequivalence study is relatively short, scheduled for less than 30 days from start to finish.

The company plans to make further updates in the coming weeks regarding its bioequivalence study preparation and scheduling as well integration of its research and development operations with Gen-Plus.

BNT23001 offers a novel approach to MS management by addressing limitations in traditional oral therapies. Its sublingual thin-film format provides:

• Convenience -- easy-to-use and portable, ideal for patients with difficulty swallowing or active lifestyles;
• Rapid absorption -- direct delivery through the sublingual mucosa for faster therapeutic action;
• Improved compliance -- a patient-friendly alternative designed to enhance adherence to prescribed regimens.

By delivering these advantages, BNT23001 aligns with Bionxt's mission to improve outcomes for patients living with chronic diseases such as MS.

About Bionxt Solutions Inc.

Bionxt Solutions is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems and active pharmaceutical ingredient development. The company's proprietary platforms -- sublingual (thin film), transdermal (skin patch) and oral (enteric-coated tablets) -- target key therapeutic areas, including autoimmune diseases, neurological disorders and longevity.

With research and development operations in North America and Europe, Bionxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. Bionxt is committed to improving health care by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.

Bionxt is listed on the Canadian Securities Exchange under the symbol BNXT and on the OTC Markets under the symbol BNXTF and trades in Germany under WKN: A3D1K3.

We seek Safe Harbor.